Mpox
12
4
7
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 42/100
8.3%
1 terminated out of 12 trials
75.0%
-11.6% vs benchmark
33%
4 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (12)
Evaluation of Effectiveness and Safety of LC16m8 Mpox Vaccine in the Democratic Republic of Congo (DRC)
New York City Observational Study of Mpox Immunity
Study of Tecovirimat for Human Mpox Virus
Validation of SDS-EDTA-Treated Chromatography Paper Strips for Mpox Sampling and Transport in DRC
Mpox Biology, Outcome, Transmission and Epidemiology - Tracking the Immune Response After mpoX vaCcination (MBOTE-TRAXX): Clinical Study to Monitor the Immunological Response Following Mpox Vaccination in the City of Kinshasa, Democratic Republic of the Congo
Assessment of the Efficacy and Safety of Tecovirimat in Patients With Monkeypox Virus Disease
Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC
A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age
Monkeypox, Biology, Outcome, Transmission and Epidemiology -Prospective Follow-up of High-risk Contacts
Mpox Comprehensive Assessment for Responsive Immunisation in Emergency Outbreaks
Observational, Prospective, Cohort Study of Mpox Infection in Brazil (NETPOX)
Break-through Infection Following Mpox vaccinatIon